Szela Mary T 4

What Happened
Mary T. Szela, CEO, President and a director of TriSalus Life Sciences, purchased 39,682 shares of TriSalus common stock on May 15, 2026. The shares were acquired in multiple open‑market transactions at prices ranging from $2.48 to $2.62, for a reported weighted average price of $2.59, totaling approximately $102,776. This was a purchase (insider buy), which many investors view as a more informative signal than routine sales.

Key Details

• Transaction date: May 15, 2026 (filed May 18, 2026) — filing appears timely.
• Transaction code: P = Purchase (open market).
• Shares bought: 39,682; weighted average price: $2.59; total consideration: ~$102,776.
• Price range: $2.48–$2.62 per share (footnote: reporting person can provide breakdown on request).
• Footnote F1: The purchase was matchable under Section 16(b) to prior sales (4,358 shares sold on Mar 11, 2026 at $4.13 and 15,944 shares at $3.85) that were sales to satisfy tax withholding on vested RSUs; the reporting person paid $27,573.70 to the issuer representing the short‑swing profit.
• Shares owned after the transaction: not disclosed in the filing.

Context

• The filing indicates ordinary open‑market purchases rather than an option exercise, grant, or gift.
• The Section 16(b) matching and payment noted in the footnote reflect compliance with short‑swing profit rules for prior tax‑withholding sales, not discretionary sales.
• For retail investors: insider purchases can be a positive signal but should be considered alongside company fundamentals and other filings.